Proteomedix granted patent for Proclarix in the USA

Proteomedix has been granted a patent for its prostate cancer test Proclarix in the USA. According to a press release issued by the company based in Schlieren in the canton of Zurich, the United States Patent and Trademark Office has granted US Patent No. 11,320,435 entitled “Method of detection proteins in human samples and uses of such methods”. According to the information from Proteomedix, the patent applies to its lead product Proclarix.

The US patent confirms the potential of Proclarix and “strengthens our intellectual property position, and highlights our commitment to innovation of biomarkers for prostate cancer diagnosis and prognosis”, explains Ralph Schiess, CSO and co-founder of Proteomedix, in the press release. The patent reflects the company’s strong position in the area of protein biomarker technology in the USA as well as other markets, while also complementing the existing patent portfolio covering the Proteomedix method that is also granted across multiple markets.

According to Proteomedix, Proclarix is a novel blood-based test. It is designed to rule out the presence of cancer or clinically significant cancer, thereby reducing the number of unnecessary biopsies. Proteomedix has presented positive study results for Proclarix. The test detected clinically significant prostate cancer with a high sensitivity of over 90 percent. Prostate cancer is the second most common cancer diagnosis in men and the fifth most-common cause of death worldwide

Proteomedix is a spin-off from the Swiss Federal Institute of Technology in Zurich (ETH) and is headquartered at the Bio-Technopark Schlieren-Zurich.